Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-23-021681
Filing Date
2023-02-14
Accepted
2023-02-14 16:21:46
Documents
2
Group Members
JEREMY C. GREENREDMILE BIOPHARMA INVESTMENTS III, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm236041d10_sc13ga.htm SC 13G/A 92745
2 EXHIBIT 99.1 tm236041d10_ex99-1.htm EX-99.1 8391
  Complete submission text file 0001104659-23-021681.txt   102841
Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

EIN.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Subject) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91191 | Film No.: 23629808
SIC: 2834 Pharmaceutical Preparations